JP2012532620A - 改良型抗血清アルブミン結合単一可変ドメイン - Google Patents

改良型抗血清アルブミン結合単一可変ドメイン Download PDF

Info

Publication number
JP2012532620A
JP2012532620A JP2012520016A JP2012520016A JP2012532620A JP 2012532620 A JP2012532620 A JP 2012532620A JP 2012520016 A JP2012520016 A JP 2012520016A JP 2012520016 A JP2012520016 A JP 2012520016A JP 2012532620 A JP2012532620 A JP 2012532620A
Authority
JP
Japan
Prior art keywords
variable domain
optionally
sec
amino acid
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520016A
Other languages
English (en)
Japanese (ja)
Inventor
エドワード、クールストック
エレナ、デ、アンジェリス
リウ、ハイクン
オリバー、ショーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2012532620A publication Critical patent/JP2012532620A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012520016A 2009-07-16 2010-07-14 改良型抗血清アルブミン結合単一可変ドメイン Pending JP2012532620A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22602809P 2009-07-16 2009-07-16
US61/226,028 2009-07-16
US30755410P 2010-02-24 2010-02-24
US61/307,554 2010-02-24
PCT/EP2010/060112 WO2011006915A2 (en) 2009-07-16 2010-07-14 Improved anti-serum albumin binding single variable domains

Publications (1)

Publication Number Publication Date
JP2012532620A true JP2012532620A (ja) 2012-12-20

Family

ID=42829253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520016A Pending JP2012532620A (ja) 2009-07-16 2010-07-14 改良型抗血清アルブミン結合単一可変ドメイン

Country Status (15)

Country Link
US (2) US8679496B2 (https=)
EP (1) EP2454285A2 (https=)
JP (1) JP2012532620A (https=)
KR (1) KR20120038494A (https=)
CN (1) CN102574914A (https=)
AU (1) AU2010272590B2 (https=)
BR (1) BR112012001681A2 (https=)
CA (1) CA2768462A1 (https=)
EA (1) EA201270174A1 (https=)
IL (1) IL217520A0 (https=)
IN (1) IN2012DN00640A (https=)
MX (1) MX2012000765A (https=)
SG (1) SG177601A1 (https=)
WO (1) WO2011006915A2 (https=)
ZA (1) ZA201200276B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517818A (ja) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2019502656A (ja) * 2015-11-13 2019-01-31 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP2020511113A (ja) * 2016-12-07 2020-04-16 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP2022520998A (ja) * 2019-02-22 2022-04-04 アンウィタ バイオサイエンシス， インク． アルブミン結合抗体及びその使用
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012072731A2 (en) * 2010-12-01 2012-06-07 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
WO2013068571A1 (en) * 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
NO2768984T3 (https=) 2015-11-12 2018-06-09
IL300122A (en) 2015-11-18 2023-03-01 Merck Sharp ַ& Dohme Llc Substances that bind to PD1 and/or LAG3
CA3003777A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1/ctla4 binders
AU2016355569B2 (en) 2015-11-18 2020-01-02 Merck Sharp & Dohme Llc CTLA4 binders
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Polynucleotides encoding relaxin
HUE070957T2 (hu) 2017-02-16 2025-07-28 Sonnet Biotherapeutics Inc Albuminkötõ domén fúziós fehérjék
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
US12202911B2 (en) 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
EP3816185A1 (en) 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
WO2021205184A1 (en) 2020-04-09 2021-10-14 Autolus Limited Polypeptide
GB202007441D0 (en) 2020-05-19 2020-07-01 Autolus Ltd Polypeptide
EP3915580A1 (en) 2020-05-29 2021-12-01 Numab Therapeutics AG Multispecific antibody
IT202000013006A1 (it) * 2020-06-01 2021-12-01 Bioreweal S R L Processo per la produzione biologica di idrogeno e/o di metano mediante assorbimento e conversione biologica di anidride carbonica.
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
JP2024504471A (ja) 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
US12459994B2 (en) 2024-04-12 2025-11-04 Paragon Therapeutics, Inc. Albumin binding proteins and methods of use

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
WO2006059106A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007066106A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2009058383A2 (en) * 2007-10-31 2009-05-07 Domantis Limited Ligand
WO2009149146A1 (en) * 2008-06-04 2009-12-10 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
WO2009149147A1 (en) * 2008-06-06 2009-12-10 Ernest Blas Betancourt System and method for regulating fuel transactions
WO2009149144A2 (en) * 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
ATE479760T1 (de) 2004-03-24 2010-09-15 Domantis Ltd Universelles signalpeptid gas1
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
WO2011006915A2 (en) * 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500034A (ja) * 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
WO2006059106A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
WO2007066106A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2009058383A2 (en) * 2007-10-31 2009-05-07 Domantis Limited Ligand
WO2009149143A1 (en) * 2008-06-03 2009-12-10 E. I. Du Pont De Nemours And Company Adhesion of polyamides to epoxy resins
WO2009149146A1 (en) * 2008-06-04 2009-12-10 Ethicon Endo-Surgery, Inc. Endoscopic drop off bag
WO2009149147A1 (en) * 2008-06-06 2009-12-10 Ernest Blas Betancourt System and method for regulating fuel transactions
WO2009149144A2 (en) * 2008-06-06 2009-12-10 Danisco Us Inc. Compositions and methods comprising variant microbial proteases

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012517818A (ja) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2019502656A (ja) * 2015-11-13 2019-01-31 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP7840836B2 (ja) 2015-11-13 2026-04-06 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US11142569B2 (en) 2015-11-13 2021-10-12 Ablynx N.V. Serum albumin-binding immunoglobulin variable domains
JP2023027258A (ja) * 2015-11-13 2023-03-01 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP7195142B2 (ja) 2015-11-13 2022-12-23 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
US11414480B2 (en) 2016-12-07 2022-08-16 Ablynx N.V. Serum albumin binding immunoglobulin single variable domains
JP2023109939A (ja) * 2016-12-07 2023-08-08 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP7417421B2 (ja) 2016-12-07 2024-01-18 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP2020511113A (ja) * 2016-12-07 2020-04-16 アブリンクス エン．ヴェー． 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
US11414481B2 (en) 2017-01-17 2022-08-16 Ablynx N.V. Serum albumin binders
US11897944B2 (en) 2017-01-17 2024-02-13 Ablynx N.V. Immunoglobulin single variable domain (ISVD) capable of binding to serum albumin
JP2022520998A (ja) * 2019-02-22 2022-04-04 アンウィタ バイオサイエンシス， インク． アルブミン結合抗体及びその使用

Also Published As

Publication number Publication date
EA201270174A1 (ru) 2012-07-30
CN102574914A (zh) 2012-07-11
WO2011006915A2 (en) 2011-01-20
MX2012000765A (es) 2012-02-13
BR112012001681A2 (pt) 2019-09-24
US20120114647A1 (en) 2012-05-10
ZA201200276B (en) 2012-09-26
IL217520A0 (en) 2012-02-29
US20140140996A1 (en) 2014-05-22
CA2768462A1 (en) 2011-01-20
EP2454285A2 (en) 2012-05-23
AU2010272590A1 (en) 2012-02-02
US8679496B2 (en) 2014-03-25
AU2010272590B2 (en) 2013-10-10
WO2011006915A3 (en) 2011-03-03
KR20120038494A (ko) 2012-04-23
IN2012DN00640A (https=) 2015-08-21
SG177601A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
US8679496B2 (en) Anti-serum albumin single variable domains
JP5766616B2 (ja) 改良型抗血清アルブミン結合変異体
JP6100315B2 (ja) 改良型抗血清アルブミン結合変異体
US20150284454A1 (en) Anti-serum albumin binding variants
JP2014501515A (ja) 改良された抗血清アルブミン結合単一可変ドメイン
AU2014200157A1 (en) Improved anti-serum albumin binding single variable domains
HK40023197A (en) Improved anti-serum albumin binding variants

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150306